296 related articles for article (PubMed ID: 31936239)
21. Larotrectinib for the treatment of TRK fusion solid tumors.
Laetsch TW; Hawkins DS
Expert Rev Anticancer Ther; 2019 Jan; 19(1):1-10. PubMed ID: 30350734
[No Abstract] [Full Text] [Related]
22. Foretinib Overcomes Entrectinib Resistance Associated with the
Nishiyama A; Yamada T; Kita K; Wang R; Arai S; Fukuda K; Tanimoto A; Takeuchi S; Tange S; Tajima A; Furuya N; Kinoshita T; Yano S
Clin Cancer Res; 2018 May; 24(10):2357-2369. PubMed ID: 29463555
[No Abstract] [Full Text] [Related]
23. Role of neurotropins in rat embryonic testis morphogenesis (cord formation).
Levine E; Cupp AS; Skinner MK
Biol Reprod; 2000 Jan; 62(1):132-42. PubMed ID: 10611077
[TBL] [Abstract][Full Text] [Related]
24. Intracellular LINGO-1 negatively regulates Trk neurotrophin receptor signaling.
Meabon JS; de Laat R; Ieguchi K; Serbzhinsky D; Hudson MP; Huber BR; Wiley JC; Bothwell M
Mol Cell Neurosci; 2016 Jan; 70():1-10. PubMed ID: 26546150
[TBL] [Abstract][Full Text] [Related]
25. Switch type I to type II TRK inhibitors for combating clinical resistance induced by xDFG mutation for cancer therapy.
Xiang S; Wang J; Huang H; Wang Z; Song X; Zhou Y; Jin F; He X; Zhang ZM; Tu Z; Ding K; Zhang Z; Lu X
Eur J Med Chem; 2023 Jan; 245(Pt 1):114899. PubMed ID: 36410169
[TBL] [Abstract][Full Text] [Related]
26. Expression of trkA, trkB, and trkC in injured and regenerating retinal ganglion cells of adult rats.
Cui Q; Tang LS; Hu B; So KF; Yip HK
Invest Ophthalmol Vis Sci; 2002 Jun; 43(6):1954-64. PubMed ID: 12037005
[TBL] [Abstract][Full Text] [Related]
27. Neuroprotective effect of insulin-like growth factor-1: effects on tyrosine kinase receptor (Trk) expression in dorsal root ganglion neurons with glutamate-induced excitotoxicity in vitro.
Li H; Dong H; Li J; Liu H; Liu Z; Li Z
Brain Res Bull; 2013 Aug; 97():86-95. PubMed ID: 23769847
[TBL] [Abstract][Full Text] [Related]
28. TrkC binds to the bone morphogenetic protein type II receptor to suppress bone morphogenetic protein signaling.
Jin W; Yun C; Kim HS; Kim SJ
Cancer Res; 2007 Oct; 67(20):9869-77. PubMed ID: 17942918
[TBL] [Abstract][Full Text] [Related]
29. The trk family of oncogenes and neurotrophin receptors.
Lamballe F; Klein R; Barbacid M
Princess Takamatsu Symp; 1991; 22():153-70. PubMed ID: 1844238
[TBL] [Abstract][Full Text] [Related]
30. Activity of Entrectinib in a Patient With the First Reported
Sigal D; Tartar M; Xavier M; Bao F; Foley P; Luo D; Christiansen J; Hornby Z; Maneval EC; Multani P
J Natl Compr Canc Netw; 2017 Nov; 15(11):1317-1322. PubMed ID: 29118225
[TBL] [Abstract][Full Text] [Related]
31. TrkC binds to the type II TGF-beta receptor to suppress TGF-beta signaling.
Jin W; Yun C; Kwak MK; Kim TA; Kim SJ
Oncogene; 2007 Dec; 26(55):7684-91. PubMed ID: 17546043
[TBL] [Abstract][Full Text] [Related]
32. Differential cross-regulation of TrkA and TrkC tyrosine kinase receptors with p75.
Ivanisevic L; Banerjee K; Saragovi HU
Oncogene; 2003 Aug; 22(36):5677-85. PubMed ID: 12944916
[TBL] [Abstract][Full Text] [Related]
33. TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions.
Roviello G; D'Angelo A; Sciortino M; Mini E; Nobili S; De Logu F; Massi D
Crit Rev Oncol Hematol; 2020 Aug; 152():103011. PubMed ID: 32521311
[TBL] [Abstract][Full Text] [Related]
34. Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer.
Kim MS; Lee WS; Jeong J; Kim SJ; Jin W
Oncotarget; 2015 Nov; 6(37):40158-71. PubMed ID: 26515594
[TBL] [Abstract][Full Text] [Related]
35. Constitutive phosphorylation of TrkC receptors in cultured cerebellar granule neurons might be responsible for the inability of NT-3 to increase neuronal survival and to activate p21 Ras.
Zirrgiebel U; Lindholm D
Neurochem Res; 1996 Jul; 21(7):851-9. PubMed ID: 8873090
[TBL] [Abstract][Full Text] [Related]
36. Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma.
Pacenta HL; Macy ME
Drug Des Devel Ther; 2018; 12():3549-3561. PubMed ID: 30425456
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.
Taylor J; Pavlick D; Yoshimi A; Marcelus C; Chung SS; Hechtman JF; Benayed R; Cocco E; Durham BH; Bitner L; Inoue D; Chung YR; Mullaney K; Watts JM; Diamond EL; Albacker LA; Mughal TI; Ebata K; Tuch BB; Ku N; Scaltriti M; Roshal M; Arcila M; Ali S; Hyman DM; Park JH; Abdel-Wahab O
J Clin Invest; 2018 Aug; 128(9):3819-3825. PubMed ID: 29920189
[TBL] [Abstract][Full Text] [Related]
38. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
Hsiao SJ; Zehir A; Sireci AN; Aisner DL
J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511
[TBL] [Abstract][Full Text] [Related]
39. Emerging roles of the neurotrophin receptor TrkC in synapse organization.
Naito Y; Lee AK; Takahashi H
Neurosci Res; 2017 Mar; 116():10-17. PubMed ID: 27697534
[TBL] [Abstract][Full Text] [Related]
40. Cellular localization of Pan-trk immunoreactivity and trkC mRNA in the enteric nervous system.
Sternini C; Su D; Arakawa J; de Giorgio R; Rickman DW; Davis BM; Albers KM; Brecha NC
J Comp Neurol; 1996 May; 368(4):597-607. PubMed ID: 8744446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
